



For immediate release: 30 April 2015

HVIVO PLC
("hVIVO" or the "Company")

Director's Dealings

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, was notified today that on 23 April 2015, Jim Winschel, a Non-Executive Director of the Company, purchased 12,350 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 330 pence per share.

Following this transaction, Mr Winschel's total interest in the Company has increased by 12,350 Ordinary Shares to a total of 15,702 Ordinary Shares, representing approximately 0.02% of the Company's issued share capital.

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (CEO)
Graham Yeatman (FD)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.